

Takashi Kohno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4967608/publications.pdf>

Version: 2024-02-01

134
papers

10,533
citations

41323

49
h-index

34964

98
g-index

137
all docs

137
docs citations

137
times ranked

15980
citing authors

#	ARTICLE	IF	CITATIONS
1	Accounting for <i>EGFR</i> Mutations in Epidemiologic Analyses of Non-Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 679-687.	1.1	1
2	Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Cancers</i> , 2022, 14, 1119.	1.7	28
3	Whole-genome Sequencing-based Lung Cancer Precision Medicine in Japan. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 10-14.	0.0	1
4	Clinical impact of genetic alterations of <i>CTNNB1</i> in patients with grade 3 endometrial endometrioid carcinoma. <i>Cancer Science</i> , 2022, 113, 1712-1721.	1.7	3
5	Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. <i>Cancer Science</i> , 2022, 113, 2763-2777.	1.7	11
6	Phasing analysis of lung cancer genomes using a long read sequencer. <i>Nature Communications</i> , 2022, 13, .	5.8	8
7	DNA hypermethylation of the <i>ZNF132</i> gene participates in the clinicopathological aggressiveness of pan-negative-type lung adenocarcinomas. <i>Carcinogenesis</i> , 2021, 42, 169-179.	1.3	9
8	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	49
9	ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation. <i>Carcinogenesis</i> , 2021, 42, 21-30.	1.3	9
10	The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. <i>Lung Cancer</i> , 2021, 152, 58-65.	0.9	22
11	Psychological disturbances and their association with sleep disturbances in patients admitted for cardiovascular diseases. <i>PLoS ONE</i> , 2021, 16, e0244484.	1.1	3
12	Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1757-1760.	0.6	5
13	<i>HSP90</i> inhibition overcomes <i>EGFR</i> amplification-induced resistance to third-generation <i>EGFR</i> TKIs. <i>Thoracic Cancer</i> , 2021, 12, 631-642.	0.8	14
14	Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1769.	1.7	21
15	Genome-Wide Chromatin Analysis of FFPE Tissues Using a Dual-Arm Robot with Clinical Potential. <i>Cancers</i> , 2021, 13, 2126.	1.7	7
16	Impact of ALK Inhibitors in Patients With <i>ALK</i> -Rearranged Nonlung Solid Tumors. <i>JCO Precision Oncology</i> , 2021, 5, 756-766.	1.5	16
17	Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy. <i>Scientific Reports</i> , 2021, 11, 10567.	1.6	7
18	Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 155, 40-45.	0.9	15

#	ARTICLE	IF	CITATIONS
19	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3916-3929.	0.4	13
20	MUSASHI ² confers resistance to third-generation EGFR tyrosine kinase inhibitor osimertinib in lung adenocarcinoma. <i>Cancer Science</i> , 2021, 112, 3810-3821.	1.7	18
21	Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2078-2090.	0.5	29
22	TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer. <i>Scientific Reports</i> , 2021, 11, 19261.	1.6	14
23	REToma: a cancer subtype with a shared driver oncogene. <i>Carcinogenesis</i> , 2020, 41, 123-129.	1.3	37
24	Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients. <i>Gynecologic Oncology</i> , 2020, 156, 203-210.	0.6	27
25	Efficacy of glutathione inhibitors for the treatment of ARID1A-deficient diffuse-type gastric cancers. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 342-347.	1.0	18
26	SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma. <i>NAR Cancer</i> , 2020, 2, zcaa005.	1.6	27
27	Genetic Determinants of Lung Cancer Prognosis in Never Smokers: A Pooled Analysis in the International Lung Cancer Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1983-1992.	1.1	10
28	Regional Right Ventricular Abnormalities Implicate Distinct Pathophysiological Conditions in Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American Heart Association</i> , 2020, 9, e018096.	1.6	3
29	Long-read sequencing for non-small-cell lung cancer genomes. <i>Genome Research</i> , 2020, 30, 1243-1257.	2.4	28
30	Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 491-502.	1.1	2
31	Heterogeneity of ARID1A expression in gastric cancer may affect patient survival and therapeutic efficacy. <i>Human Pathology</i> , 2020, 101, 80-81.	1.1	3
32	BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma. <i>Modern Pathology</i> , 2020, 33, 1660-1668.	2.9	9
33	Clonal Hematopoiesis From Next Generation Sequencing of Plasma From a Patient With Lung Adenocarcinoma: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 113.	1.3	3
34	Precision medicine for ovarian clear cell carcinoma based on gene alterations. <i>International Journal of Clinical Oncology</i> , 2020, 25, 419-424.	1.0	12
35	Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1594-1607.	0.5	81
36	Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. <i>Gynecologic Oncology</i> , 2019, 155, 489-498.	0.6	21

#	ARTICLE	IF	CITATIONS
37	Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	1.5	14
38	Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. <i>Cancer Cell</i> , 2019, 35, 177-190.e8.	7.7	201
39	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10025-10030.	3.3	41
40	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. <i>Cancer Science</i> , 2019, 110, 1480-1490.	1.7	238
41	Endometrial cancer arising after complete remission of uterine malignant lymphoma: A case report and mutation analysis. <i>Gynecologic Oncology Reports</i> , 2019, 28, 50-53.	0.3	2
42	Characterization of cancer omics and drug perturbations in panels of lung cancer cells. <i>Scientific Reports</i> , 2019, 9, 19529.	1.6	13
43	Mechanisms of Lung Carcinogenesis Associated with Interstitial Pneumonia. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 1134-1139.	0.0	0
44	Primary adenocarcinoma of the trachea revealing a mucinous bronchial gland cell origin. <i>Pathology Research and Practice</i> , 2018, 214, 796-799.	1.0	8
45	Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response. <i>Scientific Reports</i> , 2018, 8, 3482.	1.6	19
46	Implementation of "clinical sequencing" in cancer genome medicine in Japan. <i>Cancer Science</i> , 2018, 109, 507-512.	1.7	31
47	Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2. <i>Cancer Treatment and Research Communications</i> , 2018, 15, 21-31.	0.7	9
48	A secondary RET mutation in the activation loop conferring resistance to vandetanib. <i>Nature Communications</i> , 2018, 9, 625.	5.8	75
49	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. <i>Surgery Today</i> , 2018, 48, 1-8.	0.7	88
50	Identification of a novel therapeutic target in driver-negative non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S218-S220.	1.3	0
51	Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial Pneumonia. <i>JCO Precision Oncology</i> , 2018, 2, 1-24.	1.5	20
52	A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing. <i>Genome Medicine</i> , 2018, 10, 44.	3.6	37
53	Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 603-608.	0.6	24
54	A Nucleolar Stress-Specific p53-miR-101 Molecular Circuit Functions as an Intrinsic Tumor-Suppressor Network. <i>EBioMedicine</i> , 2018, 33, 33-48.	2.7	14

#	ARTICLE	IF	CITATIONS
55	Gene aberration profile of tumors of adolescent and young adult females. <i>Oncotarget</i> , 2018, 9, 6228-6237.	0.8	7
56	Mitotic catastrophe is a putative mechanism underlying the weak correlation between sensitivity to carbon ions and cisplatin. <i>Scientific Reports</i> , 2017, 7, 40588.	1.6	29
57	An Oncogenic <i>ALK</i> Fusion and an <i>RRAS</i> Mutation in <i>KRAS</i> Mutation-Negative Pancreatic Ductal Adenocarcinoma. <i>Oncologist</i> , 2017, 22, 158-164.	1.9	24
58	Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. <i>Modern Pathology</i> , 2017, 30, 797-809.	2.9	149
59	Significantly mutated genes and regulatory pathways in SCLC—a meta-analysis. <i>Cancer Genetics</i> , 2017, 216-217, 20-28.	0.2	14
60	Long-term expansion of alveolar stem cells derived from human iPS cells in organoids. <i>Nature Methods</i> , 2017, 14, 1097-1106.	9.0	198
61	Common <i>TDP1</i> Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium. <i>Clinical Cancer Research</i> , 2017, 23, 7550-7557.	3.2	6
62	The genomic and epigenomic landscape in thymic carcinoma. <i>Carcinogenesis</i> , 2017, 38, 1084-1091.	1.3	46
63	Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 42-50.	5.2	252
64	Genes involved in development and differentiation are commonly methylated in cancers derived from multiple organs: A single-institutional methylome analysis using 1007 tissue specimens. <i>Carcinogenesis</i> , 2017, 38, bgw209.	1.3	16
65	Sequencing and phasing cancer mutations in lung cancers using a long-read portable sequencer. <i>DNA Research</i> , 2017, 24, 585-596.	1.5	53
66	Advances in targeted therapy and immunotherapy for treatment of lung cancer. <i>Annals of Cancer Research and Therapy</i> , 2016, 24, 1-6.	0.1	1
67	Gene aberrations for precision medicine against lung adenocarcinoma. <i>Cancer Science</i> , 2016, 107, 713-720.	1.7	174
68	Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. <i>Molecular Cancer</i> , 2016, 15, 73.	7.9	47
69	Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. <i>Nature Communications</i> , 2016, 7, 12451.	5.8	49
70	Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung. <i>Journal of Thoracic Oncology</i> , 2016, 11, 261-265.	0.5	71
71	Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues. <i>Journal of Thoracic Oncology</i> , 2016, 11, 203-212.	0.5	21
72	Oncogenic Fusion Gene <i>CD74-NRG1</i> Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit. <i>Cancer Research</i> , 2016, 76, 974-983.	0.4	53

#	ARTICLE	IF	CITATIONS
73	Targeting p300 Addiction in <i>CBP</i> -Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of <i>MYC</i> Expression. <i>Cancer Discovery</i> , 2016, 6, 430-445.	7.7	129
74	Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. <i>PLoS Medicine</i> , 2016, 13, e1002162.	3.9	148
75	An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1037-1048.	0.5	103
76	The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells. <i>Scientific Reports</i> , 2015, 5, 11305.	1.6	29
77	Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment. <i>Genome Biology</i> , 2015, 16, 66.	3.8	66
78	Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks. <i>Biomolecules</i> , 2015, 5, 2464-2476.	1.8	20
79	Comprehensive genomic profiles of small cell lung cancer. <i>Nature</i> , 2015, 524, 47-53.	13.7	1,634
80	Development of Lung Adenocarcinomas with Exclusive Dependence on Oncogene Fusions. <i>Cancer Research</i> , 2015, 75, 2264-2271.	0.4	38
81	Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing. <i>Carcinogenesis</i> , 2015, 36, 616-621.	1.3	73
82	KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer. <i>Cancer Research</i> , 2015, 75, 3936-3945.	0.4	65
83	Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8093-8093.	0.8	3
84	Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 156-64.	1.3	173
85	Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 3087-3093.	3.2	169
86	TSPAN12 is a critical factor for cancer-fibroblast cell contact-mediated cancer invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18691-18696.	3.3	55
87	RET and other genes: therapeutic targets in lung adenocarcinoma. <i>Lung Cancer Management</i> , 2014, 3, 219-226.	1.5	0
88	A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. <i>Carcinogenesis</i> , 2014, 35, 2452-2456.	1.3	41
89	Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2014, 135, 319-334.	2.3	57
90	A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 4784-4793.	3.2	33

#	ARTICLE	IF	CITATIONS
91	Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1324-1331.	0.5	150
92	Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 622-630.	0.5	50
93	Chromatin-regulating proteins as targets for cancer therapy. <i>Journal of Radiation Research</i> , 2014, 55, 613-628.	0.8	28
94	Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. <i>Nucleic Acids Research</i> , 2014, 42, 13557-13572.	6.5	102
95	Proposal for a Synthetic Lethality Therapy Using the Paralog Dependence of Cancer Cells' Response. <i>Cancer Research</i> , 2014, 74, 4948-4949.	0.4	6
96	TSPAN2 Is Involved in Cell Invasion and Motility during Lung Cancer Progression. <i>Cell Reports</i> , 2014, 7, 527-538.	2.9	33
97	SWI/SNF Factors Required for Cellular Resistance to DNA Damage Include ARID1A and ARID1B and Show Interdependent Protein Stability. <i>Cancer Research</i> , 2014, 74, 2465-2475.	0.4	140
98	MAX Inactivation in Small Cell Lung Cancer Disrupts MYC-SWI/SNF Programs and Is Synthetic Lethal with BRG1. <i>Cancer Discovery</i> , 2014, 4, 292-303.	7.7	153
99	C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe. <i>Radiotherapy and Oncology</i> , 2014, 111, 222-227.	0.3	62
100	NEK9-dependent proliferation of cancer cells lacking functional p53. <i>Scientific Reports</i> , 2014, 4, 6111.	1.6	15
101	Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor. <i>Carcinogenesis</i> , 2013, 34, 2486-2497.	1.3	61
102	Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 802-816.	1.5	106
103	A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1. <i>Cancer Research</i> , 2013, 73, 5508-5518.	0.4	225
104	Combination of Protein Coding and Noncoding Gene Expression as a Robust Prognostic Classifier in Stage I Lung Adenocarcinoma. <i>Cancer Research</i> , 2013, 73, 3821-3832.	0.4	52
105	RET fusion gene: Translation to personalized lung cancer therapy. <i>Cancer Science</i> , 2013, 104, 1396-1400.	1.7	106
106	Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Science</i> , 2013, 104, 896-903.	1.7	67
107	CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. <i>Oncology Reports</i> , 2013, 30, 1675-1680.	1.2	19
108	ROS1-Rearranged Lung Cancer. <i>American Journal of Surgical Pathology</i> , 2013, 37, 554-562.	2.1	155

#	ARTICLE	IF	CITATIONS
109	DNA Methylation Profiles at Precancerous Stages Associated with Recurrence of Lung Adenocarcinoma. <i>PLoS ONE</i> , 2013, 8, e59444.	1.1	52
110	Histone Acetyltransferases (HATs) Involved in Non-Homologous End Joining as a Target for Radiosensitization. , 2013, , .		2
111	Mouse Model for ROS1-Rearranged Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e56010.	1.1	54
112	Identification of Genes Upregulated in <i>ALK</i> -Positive and <i>EGFR/KRAS/ALK</i> -Negative Lung Adenocarcinomas. <i>Cancer Research</i> , 2012, 72, 100-111.	0.4	702
113	c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas. <i>Journal of Thoracic Oncology</i> , 2012, 7, 331-339.	0.5	136
114	Garcinol, a Histone Acetyltransferase Inhibitor, Radiosensitizes Cancer Cells by Inhibiting Non-Homologous End Joining. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 815-821.	0.4	68
115	KIF5B-RET fusions in lung adenocarcinoma. <i>Nature Medicine</i> , 2012, 18, 375-377.	15.2	753
116	A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population. <i>Nature Genetics</i> , 2012, 44, 900-903.	9.4	166
117	CBP and p300 Histone Acetyltransferases Contribute to Homologous Recombination by Transcriptionally Activating the BRCA1 and RAD51 Genes. <i>PLoS ONE</i> , 2012, 7, e52810.	1.1	46
118	Genetic Polymorphisms Underlying Lung Cancer Susceptibility and Therapeutic Response. <i>Genes and Environment</i> , 2012, 34, 94-100.	0.9	1
119	Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1226-1234.	2.1	264
120	Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1677-1686.	0.5	56
121	The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non-Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three Cohorts. <i>Clinical Cancer Research</i> , 2011, 17, 1875-1882.	3.2	187
122	Essential Factors for Incompatible DNA End Joining at Chromosomal DNA Double Strand Breaks In Vivo. <i>PLoS ONE</i> , 2011, 6, e28756.	1.1	14
123	Association of DNA Repair Gene Polymorphisms With Response to Platinum-Based Doublet Chemotherapy in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4945-4952.	0.8	67
124	The ACF1 Complex Is Required for DNA Double-Strand Break Repair in Human Cells. <i>Molecular Cell</i> , 2010, 40, 976-987.	4.5	182
125	Whole Genome Comparison of Allelic Imbalance between Noninvasive and Invasive Small-Sized Lung Adenocarcinomas. <i>Cancer Research</i> , 2009, 69, 1615-1623.	0.4	33
126	A gene-alteration profile of human lung cancer cell lines. <i>Human Mutation</i> , 2009, 30, 1199-1206.	1.1	113

#	ARTICLE	IF	CITATIONS
127	Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. <i>Human Mutation</i> , 2008, 29, 617-622.	1.1	226
128	Association of p16 Homozygous Deletions with Clinicopathologic Characteristics and EGFR/KRAS/p53 Mutations in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 3746-3753.	3.2	30
129	Involvement of Ku80 in microhomology-mediated end joining for DNA double-strand breaks in vivo. <i>DNA Repair</i> , 2007, 6, 639-648.	1.3	26
130	Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: Deduction from structural analysis of breakpoints for deletions. <i>DNA Repair</i> , 2006, 5, 1273-1281.	1.3	35
131	Frequent EGFR mutations in brain metastases of lung adenocarcinoma. <i>International Journal of Cancer</i> , 2006, 119, 1491-1494.	2.3	183
132	Association of habitual smoking and drinking with single nucleotide polymorphism (SNP) in 40 candidate genes: data from random population-based Japanese samples. <i>Journal of Human Genetics</i> , 2005, 50, 62-68.	1.1	30
133	Mutations and deletions of the CBP gene in human lung cancer. <i>Clinical Cancer Research</i> , 2005, 11, 512-9.	3.2	88
134	Absence of hSNF5/INI1 mutation in human lung cancer. <i>Cancer Letters</i> , 2000, 153, 57-61.	3.2	17